With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

ACTION3 is a pivotal multicentre, randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in ...

Discover why monk fruit sweetener might be the healthier alternative to regular sugar. Understand the nutritional profiles, ...

In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...

AMG Frontier Small Cap Growth Fund underperformed in Q3 2025. Click here to discover key detractors and top contributors.

Granules India share price will remain in focus on December 15 following the company received an Establishment Inspection ...

Four pharma stocks to watch today as Lupin signs a peptide API deal, Dr Reddy’s and Aurobindo face FDA observations, and ...

The Philadelphia Phillies’ superstar might have risked "neurological complications” with an unapproved health procedure.

Pro-life groups are holding the U.S. Food and Drug Administration and its commissioner Marty Makary accountable for leaving ...

Cynata Therapeutics has achieved a major catalyst for 2025 by completing patient enrolment in its Phase II clinical trial of ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would ...